Suriphon Singha/iStock via Getty Images
- Gilead Sciences (NASDAQ:GILD) has entered into a collaboration with Genesis Therapeutics for the discovery of small molecule drug candidates across multiple targets using Genesis’s generative and predictive AI platform, GEMS.
- Under the deal, Genesis will receive an upfront payment of $35M across three targets, with Gilead having the option to nominate additional targets for a predetermined per-target fee. Genesis will also be eligible to receive various milestone payments plus tiered royalties on sales if any drug candidates are successfully commercialized, according to a statement.
- The transaction is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by around $0.02.
